{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:59:56Z","timestamp":1791500396673,"version":"4.3.4"},"reference-count":66,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T00:00:00Z","timestamp":1422576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Imatinib was the first BCR\u2010ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more potent BCR\u2010ABL1 TKIs has raised expectations regarding the speed and depth of response. This review discusses how molecular monitoring is being used as an integral part of the treatment regimen to achieve improved outcomes in patients with CML. The long\u2010term prognostic implications of achieving early molecular response to TKI therapy and the feasibility of maintaining treatment\u2010free remission will also be discussed in light of current clinical data. Am. J. Hematol. 90:242\u2013249, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23902","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T07:52:11Z","timestamp":1416469931000},"page":"242-249","source":"Crossref","is-referenced-by-count":14,"title":["Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment\u2010free remission"],"prefix":"10.1002","volume":"90","author":[{"given":"Harry P.","family":"Erba","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham (UAB) and UAB Comprehensive Cancer Center Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191506"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2237408"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8\u2010year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_9_8_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V1.2015. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed on October 16 2014."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745525"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","unstructured":"LarsonRA KimDW JootarS et al.ENESTnd 5\u2010y update: Long\u2010term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with frontline nilotinib (NIL) vs imatinib (IM).J Clin Oncol2014;32(abstr 7073).","DOI":"10.1200\/jco.2014.32.15_suppl.7073"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","unstructured":"CortesJE HochhausA KimDW et al.Four\u2010year (yr) follow\u2010up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) receiving dasatinib or imatinib: Efficacy based on early response.Blood2013;122(abstr 653).","DOI":"10.1182\/blood.V122.21.653.653"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9176"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood.V120.21.69.69","article-title":"Assessment of early molecular response as a predictor of long\u2010term clinical outcomes in the phase 3 BELA study","volume":"120","author":"Brummendorf TH","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.104"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.185"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23560"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.741577"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.812034"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5217"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12187"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095158"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.136"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","unstructured":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia.Interferon alfa\u20102a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.N Engl J Med1994;330:820\u2013825.","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-532"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.906.906"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11223"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.214"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.017"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long term follow\u2010up after imatinib cessation for patients in deep molecular response: The update results of the STIM1 study","volume":"122","author":"Mahon FX","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-280206"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902926973"},{"key":"e_1_2_9_50_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2121.2121","article-title":"Imatinib discontinuation following a major molecular response: Impact of interferon alpha and leukemia stem cell burden (the STOP study)","volume":"112","author":"Koskenvesa P","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_51_1","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23427"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462291"},{"key":"e_1_2_9_55_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7025","article-title":"Effect of continued imatinib (IM) in pts with detectable BCR\u2010ABL after\u2009\u2265\u20092 years on study on deep molecular responses (MR): 36\u2010month update from ENESTcmr","volume":"32","author":"Spector N","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_56_1","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)\u2010chronic myeloid leukemia (CML) patients with stable undetectable BCR\u2010ABL transcripts","volume":"120","author":"Rea D","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3074"},{"key":"e_1_2_9_58_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124","article-title":"Treatment\u2010free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath","volume":"32","author":"Mahon FX","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_59_1","article-title":"First interim analysis of a pan\u2010European STOP trial using standardized molecular criteria: Results of the EURO\u2010SKI trial","volume":"99","author":"Saussele S","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_9_60_1","article-title":"Discontinuation of dasatinib in patients with CML who have maintained complete molecular response for at least one year: Results from a prospective discontinuation (DADI) trial","volume":"99","author":"Kimura S","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057521"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2947"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.08.003"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07737"},{"key":"e_1_2_9_66_1","first-page":"221","article-title":"Combination of the hedgehog pathway inhibitor LDE225 and nilotinib targets the leukemic stem cell population in chronic myeloid leukaemia","volume":"96","author":"David A","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt006"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23902","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:49:49Z","timestamp":1696610989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,30]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1002\/ajh.23902"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23902","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,30]]}}}